RHOA and neoplasm: Seemingly restricted to tumor cells (38), RHOA mutations are present in approximately 50-70% of AITL cases, with the G17V missense mutation (valine substitution for the 17th residue (glycine)), accounting for 91% of RHOA mutations (14).